



# An Open PHACTS Knime workflow to collect compound data from public databases

Daniela Digles, Gerhard F. Ecker daniela.digles@univie.ac.at


24. Wissenschaftliche Tagung der ÖPhG, 14.09.2015








#### **Data collection**













Image provided by the Open PHACTS Foundation





#### **Data collection**








#### Workflow tools

- Single "blocks" for each data processing step (e.g. data reader, calculations, visualization, …)
- Blocks are placed via drag-and-drop and connected to each other with arrows.
- Comercial (e.g. Pipeline Pilot) and free tools (e.g. KNIME) available







#### **KNIME**


- KNIME Analytics Platform
- Available from www.knime.org
- Open source data analytics, reporting and integration platform
- Workflows can be built by connecting "Nodes"
- Open PHACTS KNIME nodes available from github: https://github.com/openphacts/OPS-Knime








## **Open PHACTS KNIME node**







## **Open PHACTS KNIME node**







## **Answering "scientific competency questions"**


- 20 questions defined at the beginning of the project.
- Azzaoui K, Jacoby E, Senger S, et al. (2013) Drug Discov. Today 18: 843 –
   852.
- Example: Give me all oxidoreductase inhibitors active <100 nM in human and mouse.</p>
- Many questions need a combination of queries to the Open PHACTS Platform.
- Workflows published: Chichester C, Digles D, Siebes R, et al. (2015) Drug Discov. Today 20: 399 – 405.





### **Example workflow**


Q10: For a given compound, summarize all similar compounds and their activities







### Workflow to collect compound data







## Collected results: compound information

- Structure search: 96 molecules, including the molecule itself.
- Compound information/classification: 1 known drug propafenone

D ▼ simila	S Chebi Class Label		S DB_description	S DB_pro	S DB_toxi	S reporte	S label
0.955	?	€ O O HAND	n.a.	n.a.	n.a.	?	1-{2-[3-(4-
1	?	,	n.a.	n.a.	n.a.	?	1-propanon
0.984	?	€ ON CIH	n.a.	n.a.	n.a.	?	1-{2-[2-Hyc
0.952	anti-arrhythmia drug	© ŏH, ch	An antiarrhythmia agent	97%	Symptoms o	HYPERHIDR	propafenon





## Collected results: bioactivity values

191 activity values (lower than 10 μM) against 33 targets.

S First(Target_name)	S First(Target_organism	■ Unique count(SMILES)	D Max*(similarity)
P-glycoprotein 1	Homo sapiens	27	1
CCRF-CEM/VCR-1000	Homo sapiens	23	1
Plasmodium falciparum	Plasmodium falciparum	7	1
Unchecked	?	6	1
Plasmodium falciparum (isolate K1 / Thailand)	Plasmodium falciparum K1	4	0.955
HERG	Homo sapiens	3	0.955
Cytochrome P450 2D6	Homo sapiens	2	0.952
Cytochrome P450 3A4	Homo sapiens	2	0.952
Cytochrome P450 1A2	Homo sapiens	2	0.952
Thrombopoietin	Homo sapiens	1	0.952
Serotonin 2b (5-HT2b) receptor	Homo sapiens	1	0.952
Thyroid stimulating hormone receptor	Homo sapiens	1	0.968
Beta-2 adrenergic receptor	Homo sapiens	1	0.952
Beta-1 adrenergic receptor	Homo sapiens	1	0.952
Norepinephrine transporter	Homo sapiens	1	0.952
Serotonin 2a (5-HT2a) receptor	Homo sapiens	1	0.952





## **Collected results: pathways for targets**

#### 98 pathways

S Unique concatenate(First(Target_name))	First(Pathway title)	Image from column1	Count(Pat
Serotonin 2b (5-HT2b) receptor, Thyroid stimulating h GPC	CR downstream signaling		8
Serotonin 2b (5-HT2b) receptor, Thyroid stimulating h GPC	CR ligand binding		8



S Unique concatenate(First(Target\_name))



## Collected results: diseases for targets

>2000 diseases in 25 disease classes

Prelamin-A/C, Thrombopoietin, Serotonin 2b (5-HT2b) receptor, T... NEOPLASM MALIGNANT

Prelamin-A/C, Thyroid stimulating hormone receptor, Norepinephri... cortex bone disorders

Serotonin 2b (5-HT2b) receptor, Beta-2 adrenergic receptor, Beta... Depressive Disorder, Major

Prelamin-A/C, Thyroid stimulating hormone receptor, Sulfonylurea ... Alzheimer Disease

Prelamin-A/C, Serotonin 2b (5-HT2b) recentor, Thyroid stimulating... Hypertension

realist A/c, serotorist 25 (5 111 25) receptor, 111 yrold samulating	rrypertension	E restretablistes the main metabolic attributes of the install resistance syntaronic, including cer
Prelamin-A/C, Serotonin 2b (5-HT2b) receptor, Sodium channel pr	Heart Failure	[Between January, 2008 and June, 2012 two patient populations were screened for the presenc
Beta-2 adrenergic receptor, Norepinephrine transporter, Serotoni	Schizophrenia	[The inverse F-BAR (IF-BAR) domain proteins srGAP1, srGAP2 and srGAP3 are implicated in neuro
Thrombopoietin, Sodium channel protein type V alpha subunit, Sulf	Cardiovascular Diseases	[Human thrombopoietin (TPO) is involved in cardiovascular disease as it regulates megakaryocyte
Prelamin-A/C, Sodium channel protein type V alpha subunit, Sulfon	Congestive heart failure	[LMNA is one of the most prevalent mutated genes in dilated cardiomyopathy, and is associated v
Prelamin-A/C, Thyroid stimulating hormone receptor, Sulfonylurea	Obesity	[Obesity-related phenotypes have been linked to human chromosomes 1q21 and 20q13, regions
Prelamin-A/C, Thyroid stimulating hormone receptor, Norepinephri	cortex bone disorders	[Measurements of NT-4/5 in rats subjected to lateral fluid percussion (LFP) TBI revealed two-thre

S First(Disease name)

S Concatenate(Disease association description)

[Several exciting recent discoveries also point to a genome-scale disruption of the epigenome that

The results of two more recent studies identify two additional human disease-associated protein

IEPLD recapitulates the main metabolic attributes of the insulin resistance syndrome, including ce

[Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial

Prelamin-A/C, Sulfonylurea receptor 2, Kir6.2, Beta-2 adrenergic r... Colorectal Cancer

Prelamin-A/C, Thyroid stimulating hormone receptor, Norepinephri... Adrenal Cortex Diseases

Prelamin-A/C, Sulfonylurea receptor 2, Kir6.2, Beta-2 adrenergic r... Diabetes Mellitus, Type 2

Thrombopoietin, Sodium channel protein type V alpha subunit, Sulf... Myocardial Infarction

[Lamin A/C is a risk biomarker in colorectal cancer.]. Sentence from MEDLINE/PubMed, a databas [Measurements of NT-4/5 in rats subjected to lateral fluid percussion (LFP) TBI revealed two-three [The aim of this study was to investigate whether genetic variation in LMNA can influence the risk [The observation of frequency differences between cases and controls in two independent samp

Prelamin-A/C, Thyroid stimulating hormone receptor, Sulfonylurea ... Neoplasm Metastasis [In conclusion, in breast carcinomas, the frequency of multiple metastasis was found to be higher [In conclusion, in breast carcinomas, the frequency of multiple metastasis was found to be higher [Using several methods we found that \$100A6 interacts with lamin A/C, a protein known to be im [Prelamin-A/C, Beta-2 adrenergic receptor, Norepinephrine transp... Carcinoma of lung [The relationship between lung cancer phenotype and lamin expression was explored further in the prelamin-A/C, Thyroid stimulating hormone receptor, Sodium chan... Recurrent Malignant Neoplasm [Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation the prelamin-A/C, Thyroid stimulating hormone receptor, Sodium chan... Recurrent Malignant Neoplasm [Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation the prelamin-A/C, Thyroid stimulating hormone receptor, Sulfonylurea ... Neoplasm [Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation the prelamin-A/C, Thyroid stimulating hormone receptor, Sulfonylurea ... Neoplasm [Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation the prelamin-A/C, Thyroid stimulating hormone receptor is a subject to the prelamin-A/C.

Prelamin-A/C, Beta-2 adrenergic receptor, Beta-1 adrenergic rece... Adenocarcinoma [Among the proteins that were identified, Rho GDP dissociation inhibitor 2, alpha-enolase, Lamin Prelamin-A/C, Beta-2 adrenergic receptor, Norepinephrine transp... Malignant neoplasm breast [As IDC constitutes approximately 70% of breast cancers seen clinically, the level of Di 12 expression [Using the dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test, we investigated the

Beta-2 adrenergic receptor, Norepinephrine transporter, Serotoni... Depression [Using the dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test, we investigated the Norepinephrine transporter, Serotonin 2a (5-HT2a) receptor, Sero... Parkinson Disease [Norepinephrine transporter (NET) binding site concentration in the LC of PD subjects was significantly assigned.





#### Conclusions

- Workflow allows the easy preparation of a first overview on known data for a compound of interest.
- New ideas for targets to test the compounds against.
  - Example: Serotonin receptor for propafenone derivatives
- Literature (Pubmed) is returned for the results.
- Methods for prioritization needed (e.g. which of the > 2000 diseases are relevant)





#### **Acknowledgements**

- Pharmacoinformatics research group, University of Vienna
  - Gerhard F. Ecker
  - Barbara Zdrazil
  - Lars Richter

- Open PHACTS KNIME
  - Ronald Siebes, VU
     Amsterdam
  - Christine Chichester, SIB
  - Evan Tzanis, QMUL







